Dermatofibroma cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
Homa Najafi (talk | contribs) No edit summary |
m (Bot: Removing from Primary care) |
||
| (2 intermediate revisions by one other user not shown) | |||
| Line 2: | Line 2: | ||
{{Dermatofibroma}} | {{Dermatofibroma}} | ||
{{CMG}}, {{AE}}{{Homa}} | {{CMG}}, {{AE}}{{Homa}} | ||
==Overview== | |||
==Cost-effectiveness of Therapy== | |||
==References== | ==References== | ||
{{Reflist|2}} | |||
{{ | {{WH}} | ||
{{WS}} | |||
| |||
[[Category: | [[Category:Medicine]] | ||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category: | [[Category:Up-To-Date]] | ||
[[Category:Dermatology]] | [[Category:Dermatology]] | ||
Latest revision as of 21:17, 29 July 2020
|
Dermatofibroma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Dermatofibroma cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Dermatofibroma cost-effectiveness of therapy |
|
Risk calculators and risk factors for Dermatofibroma cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2]